Literature DB >> 11928712

Neuronal nicotinic receptor and psychiatric disorders: functional and behavioral effects of nicotine.

Hiroaki Araki1, Katsuya Suemaru, Yutaka Gomita.   

Abstract

Both retrospective and prospective clinical studies have demonstrated positive associations of smoking with psychiatric disorders such as schizophrenia, depression and anxiety. Neuronal nicotinic acetylcholine receptors (nAChR) belong to a family of ligand-gated ion channels that are widely distributed in the brain. The pre-synaptically located nAChR, which are composed of alpha3 or alpha4 subunits in combination with beta2 subunit on axon terminals, modulate the multiple transmission release. Several studies indicated which individual nicotinic receptor subtype is responsible for mediating each of the behavioral effects of nicotine. A reduced number of alpha7 nicotinic receptor subtypes in the hippocampus were reported in schizophrenic patients. In addition, it was assumed that nicotine provided useful therapeutic treatment for a variety of cognitive impairments including those found in Alzheimer's disease, schizophrenia and attention deficit hyperactive disorder. Both alpha7 and alpha4beta2 nicotinic receptors in the hippocampus are involved in these phenomena. In the genetic depressive rats, nicotine showed antidepressant-like effects in forced swim models of depression, suggesting the involvement of alpha4beta2 nicotinic receptor in this phenomenon. Thus, it appears likely that pre-synaptic nAChR on monoaminergic fibers are composed of alpha3 or alpha4 subunits in combination with the beta2 subunit, and these subunit compositions mediate dopaminergic and noradrenergic release, and glutamate is mainly controlled by the alpha7 subunit. All these findings suggest that nicotine and other nicotinic drugs warrant further study for possible clinical prescription to psychiatric disorders.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11928712     DOI: 10.1254/jjp.88.133

Source DB:  PubMed          Journal:  Jpn J Pharmacol        ISSN: 0021-5198


  11 in total

1.  Galantamine in the treatment of minor depression with mild to moderate Alzheimer's dementia in an elderly woman.

Authors:  Kannayiram Alagiakrishnan
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2010

2.  Cholinergic blockade under working memory demands encountered by increased rehearsal strategies: evidence from fMRI in healthy subjects.

Authors:  Bianca Voss; Renate Thienel; Martina Reske; Thilo Kellermann; Abigail J Sheldrick; Sarah Halfter; Katrin Radenbach; Nadim J Shah; Ute Habel; Tilo T J Kircher
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-10-18       Impact factor: 5.270

Review 3.  The role of dopaminergic agents in improving quality of life in major depressive disorder.

Authors:  Waguih William IsHak; Michael Davis; Jessica Jeffrey; Konstantin Balayan; Robert N Pechnick; Kara Bagot; Mark Hyman Rapaport
Journal:  Curr Psychiatry Rep       Date:  2009-12       Impact factor: 5.285

4.  Predicted Impact of Nicotine Reduction on Smokers with Affective Disorders.

Authors:  Diann E Gaalema; Mollie E Miller; Jennifer W Tidey
Journal:  Tob Regul Sci       Date:  2015-07

Review 5.  Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs.

Authors:  Mark J Millan
Journal:  Neurotherapeutics       Date:  2009-01       Impact factor: 7.620

6.  Attenuation of Compulsive-Like Behavior Through Positive Allosteric Modulation of α4β2 Nicotinic Acetylcholine Receptors in Non-Induced Compulsive-Like Mice.

Authors:  Swarup Mitra; Mckenzie Mucha; Shailesh N Khatri; Richard Glenon; Marvin K Schulte; Abel Bult-Ito
Journal:  Front Behav Neurosci       Date:  2017-01-05       Impact factor: 3.558

7.  Partial nicotinic acetylcholine (alpha4beta2) agonists as promising new medications for smoking cessation.

Authors:  J Singh; Salil Budhiraja
Journal:  Indian J Pharmacol       Date:  2008-10       Impact factor: 1.200

8.  Cotinine: Beyond that Expected, More than a Biomarker of Tobacco Consumption.

Authors:  Valentina Echeverria Moran
Journal:  Front Pharmacol       Date:  2012-10-10       Impact factor: 5.810

9.  The expression of nicotinic receptor alpha7 during cochlear development.

Authors:  Scott W Rogers; Elizabeth J Myers; Lorise C Gahring
Journal:  Brain Behav       Date:  2012-08-23       Impact factor: 2.708

10.  Extended use of nicotine replacement therapy to maintain smoking cessation in persons with schizophrenia.

Authors:  W Dale Horst; Michael W Klein; Denise Williams; Steven F Werder
Journal:  Neuropsychiatr Dis Treat       Date:  2005-12       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.